Regulatory Strategy Consulting

Attain the right support at any stage of the drug development process and have peace-of-mind with the proven regulatory knowledge needed for success.

MMS strategists provide regulatory intelligence through the collection, analysis, and interpretation of publicly-available and experience-based regulatory information. We work directly with you to create an actionable regulatory strategy to support optimal progress and development.

Phase Specific Strategy
  • Early Development Strategy Consulting: Consulting on early clinical development from preclinical/first in human to prior to the end of phase 2
  • Clinical/Late-Stage Strategy Consulting: Consulting on clinical development from Phase 2 to Marketing Application
  • Establishment/Lifecycle Consulting: Consulting on product launch, maintenance, or further development after product licensing
Expedited and Incentivized Development Strategy
  • Expedited Development Strategy Consulting: Consulting on FDA (fast track, breakthrough/RMAT, priority review, accelerated approval) and EMA (PRIME designation, accelerated assessment, ATMP development) programs
  • Incentivized Development Strategy Consulting: Consulting for development programs of eligible drugs for orphan, pediatric, QIDP, LPAD pathways/designation, and other FDA and EMA programs eligible for incentives
Pediatric Disease Development Strategy

MMS supports the development of waiver or deferral requests, pediatric investigational plans (PIPs) and pediatric study plans (PSPs), incorporation of agency feedback, and pediatric written requests (PWR) acceptance, amendment, or annotation to support an exclusivity claim.

Label Development Strategy

MMS experts provide trusted label development leadership, including:​

  • Assessment and evaluation of predecessor labeling​
  • Discovery questions to contribute to identification of applicable labeling content​
  • Advising on labeling to support clinical trials​
  • Early (aspirational) label development​
  • Label development in support of a marketing authorization (prescription or over the counter [OTC])
  • Label development in support of a 505B2 or ANDA (FDA) or Hybrid, Variation, or Extension (EMA)
  • Other post-marketing label updates
Strategic Support for Meeting Requests and Packages

MMS provides preliminary communications with global health authorities, preparation of meeting questions and rationales, assistance with meeting packages, meeting preparation, interpretation of responses from the agency, and follow-up.

Area-of-Expertise Strategy
  • Therapeutic Area/Expert Consulting: Includes providing regulatory strategists with therapeutic area-specific expertise or requests for consulting with key opinion leaders or members of the MMS Scientific Advisory Board.
  • Chemistry and Manufacturing Controls (CMC) Strategy Consulting: Includes Quality by Design (QbD) consulting, CMC consulting to support drug substance (DS), drug product (DP) formulation, development and manufacturing, validation activities pre- and post-approval, gap analysis, and technology transfers. CMC consulting to support the preparation and submission of dossiers, including INDs, NDAs, ANDAs, MAAs, NDS, Abbreviated New Drug Submission (ANDS), DMF, ASMF, IMPD, post-approval submissions (CBE-0, CBE-30, PAS, Annual Report), RTQs, HA meetings, CMC global environmental analyses, and assessment of impurities or degradants, etc.
  • Nonclinical Strategy Consulting: Includes nonclinical program design, drug discovery development plan, risk and benefit assessment, safety assessment, nonclinical study analysis, NOAEL determination assessment of impurities or degradants, gap assessment, nonclinical consulting to support the preparation of dossiers, including INDs, NDAs, ANDAs, MAAs, NDS, ANDS, DMF, ASMF, IMPD, RTQs, HA meetings, or nonclinical strategy for 505(b)(2) submissions.

Suggested For You

perspectives

July 1st, 2025

Why Real-Time Data Access Matters (and How to Make the Most of It)

webinar

July 31st, 2025

Design, Data, and Decisions in Oncology Trials

perspectives

June 24th, 2025

Why Now Is the Time for Specialized, Data-Focused CRO Partners

news

June 19th, 2025

MMS Wins in the 2025 Fierce CRO Awards for Excellence in Client Service and Partnership and Dr. Uma Sharma Named CRO Champion 

perspectives

June 17th, 2025

Solving Data Complexity with Real-Time Insights, Predictive AI, and Smarter Decision-Making with Datacise

regulatory intelligence

June 16th, 2025

Key MedDRA Coding Gaps Highlighted at the ISCTM 2025 Scientific Meeting

perspectives

June 10th, 2025

Applying Artificial Intelligence (AI) and Real-World Evidence to Boost Efficiency in Patient Safety Narratives 

perspectives

June 3rd, 2025

Choosing the Right Strategy: Parallel, Sequential, and Staggered Regulatory Submissions 

news

May 28th, 2025

MMS Named Finalist for Fierce CRO Award in Excellence in Client Service and Partnership, CEO shortlisted for the CRO Champion Award 

perspectives

May 28th, 2025

A Season of Change: Why the REMS Industry Consortium Matters More Than Ever

perspectives

May 20th, 2025

Navigating FDA OMOR Meetings: A Comprehensive Guide to Type X, Y, and Z Meetings for OTC Drug Sponsors

perspectives

May 6th, 2025

Why Clinical Trial Simulation Is Reshaping Drug Development: A Q&A with Dr. Aiden Flynn